EDAP TMS SA (EDAP) is presently accelerating adoption of HIFU therapy as a new standard of care for localized prostate cancer in Europe where the company is the clear market leader while securing US approval through an active FDA Clinical Study at leading urology centers. EDAP announced today the submission of its Pre-Market Approval (PMA) …Read More